The Changing Structure Of The Pharmaceutical Industry
- 1 January 2004
- journal article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 23 (1), 10-22
- https://doi.org/10.1377/hlthaff.23.1.10
Abstract
Rising research and development (R&D) expenditures by pharmaceutical companies are, in part, a consequence of changing industry structure, particularly the rise of the biotechnology sector. The creation of a market for biomedical science and increased vertical competition within the industry are likely to spur innovation and raise productivity, but they also could induce socially wasteful spending and weaken academic science. With innovation increasingly dependent on financially vulnerable firms and complex contractual arrangements, R&D investment might be becoming more sensitive to price controls or other cost containment measures.Keywords
This publication has 5 references indexed in Scilit:
- Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug DiscoveryJournal of Industrial Economics, 1998
- Can Patents Deter Innovation? The Anticommons in Biomedical ResearchScience, 1998
- Cost of innovation in the pharmaceutical industryJournal of Health Economics, 1991
- Standing on the Shoulders of Giants: Cumulative Research and the Patent LawJournal of Economic Perspectives, 1991
- The Matthew Effect in ScienceScience, 1968